Cargando…
Exacerbation of Chronic Spontaneous Urticaria Following Coronavirus Disease 2019 (COVID-19) Vaccination in Omalizumab-Treated Patients
BACKGROUND: The rapid development and rollout of vaccines against coronavirus disease 2019 (COVID-19) has led to more than half of the world's population being vaccinated to date. Real-world data have reported various adverse cutaneous reactions, including delayed-onset urticaria, which was hig...
Autores principales: | Lee, Ji-Hyang, Shin, Eunyong, Kim, Hyun-Kyoung, Song, Woo-Jung, Kwon, Hyouk-Soo, Kim, Tae-Bum, Cho, You Sook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176887/ https://www.ncbi.nlm.nih.gov/pubmed/37182571 http://dx.doi.org/10.1016/j.jaip.2023.04.050 |
Ejemplares similares
-
Impact of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap on the prognosis of coronavirus disease 2019
por: Shin, Eunyong, et al.
Publicado: (2022) -
OMALIZUMAB IN TREATMENT-RESISTANT CHRONIC SPONTANEOUS URTICARIA
por: Godse, Kiran V
Publicado: (2011) -
Profile of omalizumab in the treatment of chronic spontaneous urticaria
por: Labrador-Horrillo, Moises, et al.
Publicado: (2015) -
Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
por: Liao, Shuang-Lu, et al.
Publicado: (2021) -
Omalizumab's efficacy and safety against chronic spontaneous urticaria
por: Özdemir, Öner
Publicado: (2023)